Cancer Research Institute

Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Jeudi, mai 9, 2024
CVR, CHRS, FDA, GAAP, TSA, Total, NCCN, Investment, Ophthalmology, Conference call, Research, CRI, Conference, ADCC, Exercise, Cancer Research Institute, Medicare Advantage, Acquisition, NPC, Medicare, COGS, Ovarian cancer, Relative value unit, Pharmaceutical industry

REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today reported financial results for the quarter ended March 31, 2024 and recent business highlights: 

Key Points: 
  • Total unit demand grew 36% in Q1 2024 compared to Q4 2023 and represented a 108% increase compared to Q1 2023.
  • Based on data from IQVIA, UDENYCA franchise market share for Q1 2024 was 25%, an increase of 10 market share points in Q1 2024 compared to Q4 2023.
  • LOQTORZI, the first and only FDA-approved treatment for recurrent, locally advanced or metastatic NPC, commercially launched on January 2, 2024.
  • Coherus projects combined R&D and SG&A expenses for 2024 to be in the range of $250 to $265 million.

Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer

Retrieved on: 
Mercredi, mai 8, 2024
Immunotherapy, CHRS, University, Ovary, Hope, Safety, CRI, Principal investigator, PD-1, CHUM, Cancer Research Institute, Patient, Cancer, DSC, Melanoma, Faculty, Therapy, ENB, Ovarian cancer, Pharmaceutical industry

Endothelin B receptor is implicated in tumorigenesis and tumor immune suppression for several solid tumors, including melanoma, ovarian, and pancreatic cancers.

Key Points: 
  • Endothelin B receptor is implicated in tumorigenesis and tumor immune suppression for several solid tumors, including melanoma, ovarian, and pancreatic cancers.
  • Dr. Stagg continued, “The iPROC study DSC brings together a group of scientific experts within the CRI community to select promising combinations and rapidly advance them to clinical trials.
  • Importantly, the DSC is not confined by a pipeline but looks to work with companies with drugs that have a strong data package.
  • For this multiparty platform study to succeed, it requires science-driven, highly collaborative, and engaged companies.

OverT Bio Raises $16 Million, Tapping Innovative Reprogramming of Immune Cells to Deliver Next-Generation Therapies

Retrieved on: 
Lundi, mai 6, 2024
Surgery, FDA, Hospitals, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Cancer, Nature, Immunology, Civilization, Survival, NYU, Cancer Research Institute, Translation, Patient, Synthetic biology, Bone marrow, Genome, Intellectual property, Investment, Gene, Pharmaceutical industry

OverT is the first to use patients’ immune response to cancer to find new receptors and targets that can be applied across the human population.

Key Points: 
  • OverT is the first to use patients’ immune response to cancer to find new receptors and targets that can be applied across the human population.
  • The team searches the entire human genome to find new ways to make cell therapies more durable and capable of destroying cancers.
  • OverT has developed unique massively parallel genetic screening, single-cell multiomic, and synthetic biology platforms to build next-generation cell therapies.
  • “The OverT team is supercharging cell therapies and finding new cures for cancer,” said Sara Choi, partner at Wing VC.

Integrated cancer biotech Infinitopes secures £12.8m seed financing to enhance its Precision Immunomics™ antigen discovery technologies to target five more cancers

Retrieved on: 
Jeudi, mai 2, 2024
Neoplasm, Medication, Cancer, Laboratory, Bias, Innovation, Big Pharma, University of Oxford, Octopus Group, Health care, Recurrence, Kindred, Vaccine, CRUK, Cancer Research Institute, Patient, LC-MS/MS, MHRA, Immune system, Associate, Precision, Growth

OXFORD, England, May 2, 2024 /PRNewswire/ -- Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, today announced the completion of a £12.8m seed funding round led by Octopus Ventures.  The round was heavily oversubscribed, also drawing in funds from Cancer Research Horizons, Cancer Research Institute, CRIS Cancer Foundation, Kindred Capital, Manta Ray, Martlet Capital, Meltwind Advisory, Saras Capital, Wilbe Capital, and expert angel investors. The total funds raised combine new equity investment and a prestigious non-dilutive award from Innovate UK's Future Economy Investor Partnership scheme.

Key Points: 
  • Since incorporation in 2021, Infinitopes has moved swiftly to cement its leadership position in cancer vaccines by overcoming three key challenges in the field.
  • Firstly, using its Precision ImmunomicsTM antigen discovery technologies, the Company can identify and rank tumour signatures, without prior bias, enabling the accurate selection of novel, synergistic tumour targets.
  • Secondly, Infinitopes continues to develop safe and effective, proprietary vector delivery systems, capable of stimulating durable T-cell responses necessary to prevent the recurrence of life-threatening cancer metastases.
  • Infinitopes' lead asset, a novel cancer vaccine called ITOP1, is scheduled to commence a phase I/IIa study in first line cancer patients in the third quarter of 2024.

Integrated cancer biotech Infinitopes secures £12.8m seed financing to enhance its Precision Immunomics™ antigen discovery technologies to target five more cancers

Retrieved on: 
Mardi, avril 30, 2024
Neoplasm, Medication, Cancer, Laboratory, Bias, Innovation, Big Pharma, University of Oxford, Octopus Group, Health care, Recurrence, Kindred, Vaccine, CRUK, Cancer Research Institute, Patient, LC-MS/MS, MHRA, Immune system, Associate, Precision, Growth

OXFORD, England, April 30, 2024 /PRNewswire/ -- Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, today announced the completion of a £12.8m seed funding round led by Octopus Ventures.  The round was heavily oversubscribed, also drawing in funds from Cancer Research Horizons, Cancer Research Institute, CRIS Cancer Foundation, Kindred Capital, Manta Ray, Martlet Capital, Meltwind Advisory, Saras Capital, Wilbe Capital, and expert angel investors. The total funds raised combine new equity investment and a prestigious non-dilutive award from Innovate UK's Future Economy Investor Partnership scheme.

Key Points: 
  • Since incorporation in 2021, Infinitopes has moved swiftly to cement its leadership position in cancer vaccines by overcoming three key challenges in the field.
  • Firstly, using its Precision ImmunomicsTM antigen discovery technologies, the Company can identify and rank tumour signatures, without prior bias, enabling the accurate selection of novel, synergistic tumour targets.
  • Secondly, Infinitopes continues to develop safe and effective, proprietary vector delivery systems, capable of stimulating durable T-cell responses necessary to prevent the recurrence of life-threatening cancer metastases.
  • Infinitopes' lead asset, a novel cancer vaccine called ITOP1, is scheduled to commence a phase I/IIa study in first line cancer patients in the third quarter of 2024.

UT Health San Antonio secures $16.4 million from CPRIT over six months, adding transformative expertise, bolstering cancer research

Retrieved on: 
Vendredi, mars 8, 2024
Doctor of Philosophy, Education, MD, Drug development, DNA repair, National Cancer Institute, Breast, University, RNA, Research institute, Ovarian cancer, Cell Systems, Health, Genetics, Anatomy, Biochemistry, Bangladesh Technical Education Board, Algorithm, Adolescence, Nursing, Neoplasm, Kitagawa, Faculty, Dentistry, HPV, Child, DNA, Chromatin, Therapy, SAN, National Institutes of Health, Mentorship, Chromosome instability, Doctor of Pharmacy, Structural biology, Vaccination, Cancer Research Institute, Molecular medicine, News, Laboratory, Research, University of Texas System, Cedars-Sinai Medical Center, Survivor, BRCA2, Cell, Howard Hughes Medical Institute, School, Cancer prevention, Luan, BRCA1, Patient, Teaching, Ewing sarcoma, Cancer, Public, Vaccine

SAN ANTONIO, March 7, 2024 /PRNewswire-PRWeb/ -- The University of Texas Health Science Center at San Antonio (UT Health San Antonio) (https://uthscsa.edu/) has secured approximately $16.4 million in funding from the Cancer Prevention and Research Institute of Texas (https://www.cprit.state.tx.us/about-us) the past six months, attracting three top cancer researchers and advancing child and adolescent cancer research.

Key Points: 
  • SAN ANTONIO, March 7, 2024 /PRNewswire-PRWeb/ -- The University of Texas Health Science Center at San Antonio (UT Health San Antonio) ( https://uthscsa.edu/ ) has secured approximately $16.4 million in funding from the Cancer Prevention and Research Institute of Texas ( https://www.cprit.state.tx.us/about-us ) the past six months, attracting three top cancer researchers and advancing child and adolescent cancer research.
  • The Mays Cancer Center at UT Health San Antonio ( https://cancer.uthscsa.edu/ ) is one of only four National Cancer Institute-designated Cancer Centers in Texas.
  • The Mays Cancer Center provides leading-edge cancer care, propels innovative cancer research and educates the next generation of leaders to end cancer in South Texas.
  • The Greehey Children's Cancer Research Institute ( https://cancer.uthscsa.edu/gccri ) is one of only two institutes in the United States dedicated solely to pediatric cancer research.

A Type of Allergy Medicine Might Help Treat Lung Cancer, Research Suggests

Retrieved on: 
Mercredi, décembre 6, 2023
DOI, Nature, Marc, Allergy, Cancer research, Patient, Lung cancer, National Institutes of Health, TARGET, Cancer, Doctor of Philosophy, Bangladesh Technical Education Board, Cancer Research Institute, Bristol Myers Squibb, Dermatitis, Immunology, Biomarker, Columbia University, Bone marrow, Immunity, Artificial intelligence, MTR, Austrian Academy of Sciences, CRI, Asthma, AACR, FAAD, Hope, Clinical trial, Mouse, Agency, Immunotherapy, Treatment of lung cancer, Human, SingHealth, Neoplasm, NSCLC, Vaccine, Pharmaceutical industry, Science, Chin, Research, MD

NEW YORK, Dec. 6, 2023 /PRNewswire-PRWeb/ -- Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer (NSCLC).

Key Points: 
  • Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer (NSCLC).
  • NEW YORK, Dec. 6, 2023 /PRNewswire-PRWeb/ -- Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer (NSCLC).
  • "Strikingly, we found that IL-4 blockade enhanced lung cancer response to checkpoint blockade in mice and in six lung cancer patients with treatment-resistant disease.
  • "In our relentless pursuit of progress, the Cancer Research Institute (CRI) proudly supports the visionary team at the Icahn School of Medicine at Mount Sinai.

Cancer Research Institute Awards Ananda Goldrath, Ph.D., with the 2023 Frederick W. Alt Award

Retrieved on: 
Lundi, octobre 30, 2023
Tata, Survival, CRI, Harvard Medical School, Leukemia, Allen Institute, Tissue-resident memory T cell, Health, Immunological Genome Project, University of California, San Diego, Cancer Research Institute, UEA School of Biological Sciences, The Pew Charitable Trusts, UCSD, Research, Creativity, Tissue, Fellow, School, Immune system, American Academy, Science, Malignancy, Cancer research, Gene, Biology, National academy, Infection, Vaccine, Management, Immunology

SEATTLE, Oct. 30, 2023 /PRNewswire/ -- The Cancer Research Institute (CRI) has awarded Ananda Goldrath, Ph.D., Executive Vice President and Director of the Allen Institute for Immunology, the 2023 Frederick W. Alt Award. This award is given to former Cancer Research Institute postdoctoral fellows who have achieved outstanding success in academia or industry for innovative research that has advanced knowledge and understanding in the field of immunology.

Key Points: 
  • SEATTLE, Oct. 30, 2023 /PRNewswire/ -- The Cancer Research Institute (CRI) has awarded Ananda Goldrath , Ph.D., Executive Vice President and Director of the Allen Institute for Immunology, the 2023 Frederick W. Alt Award.
  • This award is given to former Cancer Research Institute postdoctoral fellows who have achieved outstanding success in academia or industry for innovative research that has advanced knowledge and understanding in the field of immunology.
  • "The Cancer Research Institute has been supporting the training of young scientists and nurturing careers for decades.
  • Dr. Goldrath will receive the award at the 2023 CRI Annual Awards Dinner on Monday, November 6, in New York City.

Brown Books Publishing Group Releases New Business Book by Entrepreneur and Former ZipRecruiter VP, Mandy Schaniel

Retrieved on: 
Vendredi, septembre 29, 2023
Communications, Entertainment, Publishing, Books, Life, Culture, Orange County, Fear, Woman, ZipRecruiter, Sale, Shaista Gohir, Baroness Gohir, Knowledge, Cancer Research Institute, Family, Wounded Warrior Project, Management

Executive leadership coach and entrepreneur Mandy Schaniel cleverly attests that the common denominator between all types of success is having the mindset that it takes to achieve it.

Key Points: 
  • Executive leadership coach and entrepreneur Mandy Schaniel cleverly attests that the common denominator between all types of success is having the mindset that it takes to achieve it.
  • Her wealth of knowledge offers an insightful roadmap to help readers overcome fear and harness leadership strength to transform their careers.
  • ABOUT THE AUTHOR: Mandy Schaniel is the founder and CEO of Schaniel Consulting Inc., providing leadership and business coaching to start-ups looking to build a culture of inclusivity, progress and success for both business and employees.
  • Her rise to leadership came early when she was recruited to join the executive team at ZipRecruiter as employee number 19.

SURGE Therapeutics Raises $32M Series B Financing to Advance Intraoperative Immunotherapy to Improve Cancer Patient Survival Outcomes Post-Surgery

Retrieved on: 
Mercredi, juillet 19, 2023
Oncology, Health, Surgery, Clinical Trials, Pharmaceutical, Biotechnology, Doctor of Philosophy, Neoplasm, SURGE, Physician, Survival, Cancer, Immunity, Bladder cancer, Immunotherapy, Patient, Khosla Ventures, Therapy, Recurrence, Cancer Research Institute, Metastasis, Pharmaceutical industry

In connection with the financing, Kouki Harasaki, Ph.D., Managing Partner at Bioluminescence Ventures, will join SURGE’s Board of Directors.

Key Points: 
  • In connection with the financing, Kouki Harasaki, Ph.D., Managing Partner at Bioluminescence Ventures, will join SURGE’s Board of Directors.
  • “Intraoperative immunotherapy is a platform approach that can potentially confer clinical benefit across multiple cancer types, using different molecules.
  • “SURGE has a unique first-mover advantage in the intraoperative immunotherapy space to potentially improve patient outcomes and become the standard of care as a seamless complement to surgery.
  • In multiple aggressive murine models of metastasizing cancer, intraoperative immunotherapy vastly improved survival benefit relative to traditional routes of administration, whether systemic or local.